全文获取类型
收费全文 | 9832篇 |
免费 | 500篇 |
国内免费 | 97篇 |
专业分类
耳鼻咽喉 | 78篇 |
儿科学 | 189篇 |
妇产科学 | 84篇 |
基础医学 | 1020篇 |
口腔科学 | 337篇 |
临床医学 | 575篇 |
内科学 | 2866篇 |
皮肤病学 | 64篇 |
神经病学 | 823篇 |
特种医学 | 310篇 |
外科学 | 1926篇 |
综合类 | 37篇 |
现状与发展 | 1篇 |
一般理论 | 1篇 |
预防医学 | 245篇 |
眼科学 | 159篇 |
药学 | 532篇 |
中国医学 | 27篇 |
肿瘤学 | 1155篇 |
出版年
2023年 | 59篇 |
2022年 | 138篇 |
2021年 | 228篇 |
2020年 | 135篇 |
2019年 | 181篇 |
2018年 | 238篇 |
2017年 | 188篇 |
2016年 | 245篇 |
2015年 | 243篇 |
2014年 | 359篇 |
2013年 | 400篇 |
2012年 | 621篇 |
2011年 | 706篇 |
2010年 | 460篇 |
2009年 | 402篇 |
2008年 | 658篇 |
2007年 | 672篇 |
2006年 | 615篇 |
2005年 | 658篇 |
2004年 | 638篇 |
2003年 | 618篇 |
2002年 | 612篇 |
2001年 | 117篇 |
2000年 | 91篇 |
1999年 | 115篇 |
1998年 | 161篇 |
1997年 | 112篇 |
1996年 | 89篇 |
1995年 | 82篇 |
1994年 | 75篇 |
1993年 | 57篇 |
1992年 | 59篇 |
1991年 | 40篇 |
1990年 | 27篇 |
1989年 | 32篇 |
1988年 | 26篇 |
1987年 | 29篇 |
1986年 | 21篇 |
1985年 | 20篇 |
1984年 | 23篇 |
1983年 | 25篇 |
1982年 | 16篇 |
1981年 | 21篇 |
1980年 | 16篇 |
1979年 | 10篇 |
1978年 | 12篇 |
1977年 | 11篇 |
1976年 | 7篇 |
1974年 | 6篇 |
1969年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
102.
A missense mutation in the proteolipid protein gene responsible for Pelizaeus--Merzbacher disease in a Japanese family 总被引:2,自引:0,他引:2
Iwaki Akiko; Muramoto Tamaki; Iwaki Toru; Furumi Hiroyasu; Dario-deLeon Maria L.; Tateishi Jun; Fukumaki Yasuyuki 《Human molecular genetics》1993,2(1):19-22
We investigated the proteolipid protein (PLP) gene of two boysin a Japanese family with PelizaeusMerzbacher disease(PMD), an X-linked neurologic disorder characterized by dysmyelinationin the central nervous system (CNS). The patients showed similarclinical signs from birth and autopsy on the elder brother confirmeda connatal type of PMD. Direct sequencing of the PLP gene andPLP mRNAs from the brain of the PMD patient revealed a G toT transition in exon V of the PLP gene, which leads to a glycineto cystein substitution at residue 220. Allele-specific oligonucleotidehybridization revealed that this mutation was also present inhis brother, but was absent in 100 X chromosomes of normal Japaneseindividuals. Northern blot analysis showed that the mRNA levelsof PLP and myelin basic protein, two major myelin proteins producedby oligodendrocytes, were much reduced in the PMD brain, hence,there was a specific loss of oligodendrocytes. It seems likelythat the substitution is responsible for PMD (connatal type)in this particular family and causes oligodendrocytes deathin the CNS. 相似文献
103.
Toru Ishikawa Masataka Murakami 《Pflügers Archiv : European journal of physiology》1995,429(5):748-750
Using whole-cell patch-clamp techniques, we demonstrate, for the first time, that rat submandibular acinar cells contain a tetraethylammonium (TEA)-insensitive, Ca2+-activated K+ conductance which is not attributable to large conductance, voltage-sensitive, Ca2+-dependent K+ channels (maxi-K+ channels). Taken together with our recent K+ efflux and fluid secretion studies in intact rat submandibular gland, we postulate that the K+ conductance reported here may be involved in the basolateral K+ efflux pathway activated by cytosolic Ca2+ concentration during secretion by this gland. 相似文献
104.
Kiyoji Kimura Ryuzo Ohno Ichita Amaki Kenichi Hattori Yutaka Hirota Akira Hoshino Michito Ichimaru Munemoto Ito Ikuo Kimura Tadashi Maekawa Toru Masaoka Toru Nakamura Makoto Ogawa Masao Oguro Kazuo Ohta Shigeyuki Osamura Masanori Shimoyama Fumimaro Takaku Yoshiro Uzuka Kazumasa Yamada 《Medical oncology (Northwood, London, England)》1986,3(1):15-24
A phase I study ofN 4-behenoyl-1-β-d-arabinofuranosylcytosine (BHAC) was conducted in 66 patients, 41 with solid tumors and 25 with hematological malignancies. The patients received either a 2-h single intravenous (i.v.) drip infusion (Schedule 1) or consecutive daily 2-h i.v. infusions (Schedule 2). In Schedule 1 the daily dose was initiated with 1.5 mg kg?1 which was escalated up to 7 mg kg?1. Side-effects were mild, and included nausea, vomiting, epilation, and hot flushes. Because of the presence of the solvent vehicle, HCO-60 and in consideration of the mechanism of action of BHAC, the dose escalation was stopped at 7 mg kg?1. In Schedule 2, the daily dose was started with 1.5 mg kg?1 which was escalated up to 8 mg kg?1 and given for 2–16 days. Myelosuppression was found to be dose-limiting toxicity. The maximum tolerated dose (MTD) in patients with non-hematological solid tumors was assumed to be 5 mg kg?1 daily × 5 days. The plasma disappearance curve of BHAC looked biphasic, and when 4 mg kg?1 of BHAC were administered the half-lives of the initial phase (t 1/2α) and the second phase (t 1/2β) were calculated as 0.798 and 5.76 h respectively. In Schedule 2 complete remission was observed in 5 out of 21 patients with acute leukemia, one partial remission in Hodgkin’s disease, and one 1-B response (Karnofsky) in thyroid papillary adenocarcinoma. 相似文献
105.
Yuki Ohya Masayoshi Tasaki Shintaro Hayashida Nobuhiro Katayama Toru Tsuchida Kazumi Kuriwaki Mitsuharu Ueda Yukihiro Inomata 《Transplantation proceedings》2021,53(4):1313-1316
BackgroundCarpal tunnel syndrome is the most common compression syndrome of the peripheral nerve. Transthyretin amyloidosis and dialysis-related β2-microglobulin amyloidosis are known causes of carpal tunnel syndrome.Case ReportA Japanese woman showed carpal tunnel syndrome 16 years after a domino liver transplantation (DLT) from the donor with hereditary transthyretin amyloidosis. DLT indication was congenital extrahepatic portosystemic shunt, and the patient had been put on maintenance hemodialysis because of chronic kidney disease 6 years before DLT. Moreover, the amyloid precursor protein of the patient was histologically confirmed not to be β2-microglobulin, but transthyretin.ConclusionsThe existence of amyloid was speculated when the patient who underwent DLT from hereditary transthyretin amyloidosis showed carpal tunnel syndrome. Additionally, elucidating the amyloid precursor protein when the patient has another cause of amyloidosis is necessary. 相似文献
106.
107.
108.
Yoshikuni Kudo Toru Egashira Fusako Takayama Yasumitsu Yamanaka Tatsuo Shimada 《Archives of toxicology》1993,67(7):502-509
To explain the mechanism of renal injury caused by liver ischemia-reperfusion, we investigated biochemical and morphological changes in the liver and kidney in rats. After reperfusion following 60 min of liver ischemia, numerous changes were found. The level of serum transaminases and lipid peroxide formation in the liver tissue increased significantly. Electron microscopic studies revealed that most of the hepatocytes had swollen mitochondria and clumping of the nuclear chromatin. The sinusoidal endothelium was disrupted and the sinusoidal lumen was filled with numerous erythrocytes. Blood endotoxin concentration, plasma lipid peroxide levels, and serum -glucuronidase activities were significantly higher than in the control group. Biochemical and morphological renal injury was also observed. Tissue lipid peroxide levels increased in both the kidney and the liver. Microscopic examination revealed damage to the renal tubules, including interstitial edema, dilatation of the lumen, and granular casts derived from necrotic cells in the proximal convoluted tubule. The levels of urinary N-acetyl--d-glucosaminidase (NAG) in the liver ischemia-reperfusion group were also higher than in the control group. These results suggest that the renal injury was caused by an increase in endotoxin, lipid peroxide, and lysosomal enzymes in the blood following the liver injury induced by the ischemia-reperfusion. 相似文献
109.
Iwase K Kato K Ohtani S Tsujimura T Hanai T Inagaki A Jimbo S Kobayashi N Yamamoto H Nagasaka A Miura K 《Breast cancer (Tokyo, Japan)》1997,4(3):155-160
The localization of Cu/Zn- and Mn-superoxide dismutase (SOD) in breast cancer tissue (12 papillotubular carcinomas, 21 solid-tubular carcinomas, 16 scirrhous carcinomas, 1 medullary carcinoma, 1 secreting carcinoma, 1 lobular carcinoma, 1 Paget's disease) was investigated via an immunohistochemical technique using antihuman Cu/Zn- and Mn-SOD antibodies in 10%formalin fixed-paraffin embedded thin sections. Both SODs stained strongly in the normal breast gland, but not clearly in many cancer tissues. Furthermore, Cu/Zn-SOD stained more strongly in well differentiated tubular carcinomas than in poorly differentiated tubular carcinomas. It tended to stain less in tumors which recurred or had a poor outcome, and in tumors with a diploid pattern on DNA flow cytometry. Mn-SOD staining was similar to that of Cu/Zn-SOD, but no significant differences among subgroups was found, since the incidence of positively staining tumors was too small in all groups. The intensity of SOD staining seems to change in relation to cell proliferation and differentiation in breast carcinoma, and may be a prognostic indicator, since SOD decreased in poorly differentiated carcinoma and in tumors which developed distant metastasis. Thus, the localization of SOD in breast cancer tissue can provide useful information for cancer treatment. 相似文献
110.
Takagaki Masao Oda Yoshifumi Miyatake Shin-Ichi Kikuchi Haruhiko Kobayashi Toru Sakurai Yoshinori Osawa Masami Mori Kenjiro Ono Koji 《Journal of neuro-oncology》1997,35(2):177-185
To plan the optimal BNCT using BSH for glioblastoma patients, the10B concentration in tumor and blood was investigated in 11newly diagnosed glioblastoma patients. All patients received 20 mg BSH/kgbody weight 2.5–16 hrs prior to tumor removal. The quantitativedistribution of 10B was determined by prompt gamma rayspectrometry and/or -track autoradiography. 10Bdistribution in tumors was heterogeneous, ± 25% of scatteringat the microscopic level, and the distribution was also heterogeneous at thetissue level. 10B concentration in blood decreased inbi-exponential decay as a function of the time after the end of theadministration. The T/B ratio showed non-exponential increase with largevariation. The maximum T/B ratio would be around 1. The tumor/normal brain(T/N) ratio of 10B concentration was 11.0 ± 3.2. The10B content in normal brain is originated in vascular10B in parenchyma, since the 10B content innormal brain to blood (N/B ratio) being compatible with the blood content inparenchyma. These values allow for BNCT, using thermal neutrons, on braintumors located less than approximately 3.3 cm in depth from the brainsurface of neutron incidence, providing that the dose on the normalendothelium is controlled to less than the tolerance limit. In ourpreliminary study of BNCT, a 31% 3-year survival was achieved overall for 16 glioblastoma patients and a 50% 2-year survival wasachieved on 8 glioblastoma patients in our recent dose escalation studybased on these data. 相似文献